Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSPPONTE NETO, Alberto Machado daCLEMENTE, Aniele Cristine OttROSA, Paula WakiRIBEIRO, Igor BragaFUNARI, Mateus PereiraNUNES, Gabriel CairoMOREIRA, LuanaSPARVOLI, Luiz GustavoCORTEZ, RamonTADDEI, Carla RomanoMANCINI, Marcio C.MOURA, Eduardo Guimaraes Hourneaux de2023-10-302023-10-302023WORLD JOURNAL OF CLINICAL CASES, v.11, n.19, p.4612-4624, 20232307-8960https://observatorio.fm.usp.br/handle/OPI/56323BACKGROUNDMetabolic syndrome is a multifactorial disease, and the gut microbiota may play a role in its pathogenesis. Obesity, especially abdominal obesity, is associated with insulin resistance, often increasing the risk of type two diabetes mellitus, vascular endothelial dysfunction, an abnormal lipid profile, hypertension, and vascular inflammation, all of which promote the development of atherosclerotic cardiovascular disease.AIMTo evaluate the outcomes of fecal microbiota transplantation (FMT) in patients with metabolic syndrome.METHODSThis was a randomized, single-blind placebo-controlled trial comparing FMT and a sham procedure in patients with metabolic syndrome. We selected 32 female patients, who were divided into eight groups of four patients each. All of the patients were submitted to upper gastrointestinal endoscopy. In each group, two patients were randomly allocated to undergo FMT, and the other two patients received saline infusion. The patients were followed for one year after the procedures, during which time anthropometric, bioimpedance, and biochemical data were collected. The patients also had periodic consultations with a nutritionist and an endocrinologist. The primary end point was a change in the gut microbiota.RESULTSThere was evidence of a postprocedural change in microbiota composition in the patients who underwent FMT in relation to that observed in those who underwent the sham procedure. However, we found no difference between the two groups in terms of the clinical parameters evaluated.CONCLUSIONThere were no significant differences in biochemical or anthropometric parameters, between the two groups evaluated. Nevertheless, there were significant postprocedural differences in the microbiota composition between the placebo group. To date, clinical outcomes related to FMT remain uncertain.engopenAccessFecal microbiota transplantationMetabolic syndromeObesityEndoscopyDiabetes mellitusEndocrinologyclostridium-difficile infectionintestinal microbiotainsulin sensitivitygut microbiomemetforminadultsarticleCopyright BAISHIDENG PUBLISHING GROUP INC10.12998/wjcc.v11.i19.4612Medicine, General & Internal